Prognostic Implication of Hyperglycemia in Myocardial Infarction and Primary Angioplasty

American Journal of Medicine

Volumn 120, Issue 7, 2007, Pages

  Worthley, Matthew I ^a   Shrive, Fiona M ^a,b   Anderson, Todd J ^a   Traboulsi, Mouhieddin ^a  

^a LIBIN CARDIOVASCULAR INSTITUTE OF ALBERTA   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

Glucose; Myocardial infarction; Primary angioplasty

Indexed keywords

ABCIXIMAB; GLUCOSE;

ADULT; AGED; ARTICLE; CARDIOGENIC SHOCK; COHORT ANALYSIS; DIABETES MELLITUS; FEMALE; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; ST SEGMENT ELEVATION; SURVIVAL;

AGED; ANGIOPLASTY; BLOOD GLUCOSE; COHORT STUDIES; ELECTROCARDIOGRAPHY; FEMALE; HOSPITAL MORTALITY; HUMANS; HYPERGLYCEMIA; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROGNOSIS;

EID: 34250834374     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2006.06.043     Document Type: Article

References (33)

1. Capes S.E., Hunt D., Malmberg K., and Gerstein H.C. Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet 355 (2000) 773-778
2. Malmberg K., Norhammer A., Wedel H., and Ryden L. Glycometabolic state at admission: Important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: Long-term results from the diabetes and insulin-glucose infusion in acute myocardial infarction (DIGAMI) study. Circulation 99 (1999) 2626-2632
3. Ravid M., Berkowicz M., and Sohar E. Hyperglycemia during acute myocardial infarction. A six-year follow-up study. JAMA 233 (1975) 807-809
4. Sala J., Masia R., Gonzalez de Molina F.J., et al., REGICOR Investigators. Short-term mortality of myocardial infarction patients with diabetes or hyperglycaemia during admission. J Epidemiol Community Health 56 (2002) 707-712
5. Svensson A.M., McGuire D.K., Abrahamsson P., and Dellborg M. Association between hyper- and hypoglycaemia and 2 year all-cause mortality risk in diabetic patients with acute coronary events. Eur Heart J 26 (2005) 1255-1261
6. Suleiman M., Hammerman H., Boulos M., et al. Fasting glucose is an important independent risk factor for 30-day mortality in patients with acute myocardial infarction: a prospective study. Circulation 111 (2005) 754-760
7. Bartnik M., Ryden L., Ferrari R., et al., Euro Heart Survey Investigators. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. Eur Heart J 25 (2004) 1880-1890
8. Foo K., Cooper J., Deaner A., et al. A single serum glucose measurement predicts adverse outcomes across the whole range of acute coronary syndromes. Heart 89 (2003) 512-516
9. Shechter M., Merz C.N., Paul-Labrador M.J., and Kaul S. Blood glucose and platelet-dependent thrombosis in patients with coronary artery disease. J Am Coll Cardiol 35 (2000) 300-307
10. Worthley M.I., Holmes A.S., Willoughby S.R., et al. The deleterious effects of hyperglycemia on platelet function in diabetic patients with acute coronary syndrome: mediation by superoxide production, resolution with intensive insulin administration. [abstr]. Circulation 108 (2003) IV-311
11. Williams S.B., Goldfine A.B., Timimi F.K., et al. Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. Circulation 97 (1998) 1695-1701
12. Leung R.C., Lundberg D.L., Rollefstad T., et al. From 911 to balloon: reduction of ischemic time in primary angioplasty by implementation of a expedited transfer pathway. [abstr]. Can J Cardiol 20 (2004) 151D
13. Antman E.M., Anbe D.T., Armstrong P.W., et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction; A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction). J Am Coll Cardiol 44 (2004) E1-E211
14. TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. N Engl J Med 312 (1985) 932-936
15. Simes R.J., Topol E.J., Holmes Jr. D.R., et al., GUSTO-I Investigators. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. Circulation 91 (1995) 1923-1928
16. Graham M.M., Faris P.D., Ghali W.A., et al., APPROACH Investigators (Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease). Validation of three myocardial jeopardy scores in a population-based cardiac catheterization cohort. Am Heart J 142 (2001) 254-261
17. Ghali W.A., Quan H., Brant R., et al., APPROACH Investigators (Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease). Comparison of 2 methods for calculating adjusted survival curves from proportional hazards models. JAMA 286 (2001) 1494-1497
18. Straumann E., Kurz D.J., Muntwyler J., et al. Admission glucose concentrations independently predict early and late mortality in patients with acute myocardial infarction treated by primary or rescue percutaneous coronary intervention. Am Heart J 150 (2005) 1000-1006
19. Kosuge M., Kimura K., Kojima S., et al. Effects of glucose abnormalities on in-hospital outcome after coronary intervention for acute myocardial infarction. Circ J 69 (2005) 375-379
20. Ishihara M., Kojima S., Sakamoto T., et al. Acute hyperglycemia is associated with adverse outcome after acute myocardial infarction in the coronary intervention era. Am Heart J 150 (2005) 814-820
21. Stone G.W., Grines C.L., Cox D.A., et al. Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Investigators. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 346 (2002) 957-966
22. Norhammar A., Tenerz A., Nilsson G., Hamsten A., Efendic S., and Ryden L. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 359 (2002) 2140-2144
23. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 329 (1993) 1615-1622
24. Mehta R.H., Harjai K.J., Cox D., et al., Primary Angioplasty in Myocardial Infarction (PAMI) Investigators. Clinical and angiographic correlates and outcomes of suboptimal coronary flow inpatients with acute myocardial infarction undergoing primary percutaneous coronary intervention. J Am Coll Cardiol 42 (2003) 1739-1746
25. Goldberg R.J., Samad N.A., Yarzebski J., Gurwitz J., Bigelow C., and Gore J.M. Temporal trends in cardiogenic shock complicating acute myocardial infarction. N Engl J Med 340 (1999) 1162-1168
26. Hochman J.S., Sleeper L.A., Webb J.G., et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. N Engl J Med 341 (1999) 625-634
27. Timmer J.R., Ottervanger J.P., de Boer M.J., et al., Zwolle Myocardial Infarction Study Group. Hyperglycemia is an important predictor of impaired coronary flow before reperfusion therapy in ST-segment elevation myocardial infarction. J Am Coll Cardiol 45 (2005) 999-1002
28. Stubbs P.J., Laycock J., Alaghband-Zadeh J., Carter G., and Noble M.I. Circulating stress hormone and insulin concentrations in acute coronary syndromes; identification of insulin resistance on admission. Clin Sci (Lond) 96 (1999) 589-595
29. Vehkavaara S., Seppala-Lindroos A., Westerbacka J., Groop P.H., and Yki-Jarvinen H. In vivo endothelial dysfunction characterizes patients with impaired fasting glucose. Diabetes Care 22 (1999) 2055-2060
30. Iwakura K., Ito H., Ikushima M., et al. Association between hyperglycemia and the no-reflow phenomenon in patients with acute myocardial infarction. J Am Coll Cardiol 41 (2003) 1-7
31. Mehta S.R., Yusuf S., Diaz R., et al., CREATE-ECLA Trial Group Investigators. Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial. JAMA 293 (2005) 437-446
32. Malmberg K., Ryden L., Efendic S., et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol 26 (1995) 57-65
33. Malmberg K., Ryden L., Wedel H., et al., DIGAMI 2 Investigators. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J 26 (2005) 650-661